Analysis of key clinical features for achieving complete remission in stage III and IV non-small cell lung cancer patients

BACKGROUND: Although development of immune checkpoint inhibitors and various molecular target agents has extended overall survival time (OS) in advanced non-small cell lung cancer (NSCLC), a complete cure remains rare. We aimed to identify features and treatment modalities of complete remission (CR)...

Descripción completa

Detalles Bibliográficos
Autores principales: Aoki, Takuya, Akiba, Takeshi, Nishiyama, Jun, Tajiri, Sakurako, Hayama, Naoki, Takahashi, Genki, Tanaka, Jun, Sato, Masako, Takiguchi, Hiroto, Tomomatsu, Hiromi, Tomomatsu, Katsuyoshi, Takihara, Takahisa, Niimi, Kyoko, Oguma, Tsuyoshi, Kohno, Mitsutomo, Masuda, Ryota, Urano, Tetsuya, Itoh, Hitoshi, Kajiwara, Hiroshi, Nakamura, Naoya, Kunieda, Etsuo, Matsumae, Mitsunori, Iwazaki, Masayuki, Asano, Koichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6873580/
https://www.ncbi.nlm.nih.gov/pubmed/31752884
http://dx.doi.org/10.1186/s12931-019-1235-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6873580/
https://www.ncbi.nlm.nih.gov/pubmed/31752884
http://dx.doi.org/10.1186/s12931-019-1235-3

Ejemplares similares